The common lung cancer called non-small cell lung cancer (NSCLC) that keeps evading an effective treatment might bow down to gene therapy from a triple therapy with two drugs and radiation, said a new study.
The study on mice recently has shown that cancers with Kirsten rat sarcoma viral oncogene homolog (KRAS) can be treated in combination with radio-theray and combining two experimental drugs.
Prof. Bo Lu of Radiation Oncology at Thomas Jefferson University, who has conducted the study suggests that there is a possibility to identify non-small cell lung cancer patients who are likely to benefit most from this combination of therapies but there is need for more research into it, he added.
The resistant KRAS mutants in NSCLC are made more susceptible to therapy in the KRAS-targeting drug with another drug that to undo the effects of the p16 mutation, said the study.
Though neither of two drugs that target KRAS and proteins in the p16 pathway has been approved, researchers hope that the research will help identify the patients who could potentially benefit from a triple-therapy treatment and their study has appeared in the Journal Clinical Cancer Research.
Bo Lu is a board-certified Radiation Oncologist at Jefferson from Vanderbilt University in Nashville, Tenn. He did his Ph.D. in Cell and Molecular Biology from Baylor School of Medicine in Houston and a Doctorate in Medicine from Shanghai Medical University in China. He is currently focusing on the integration of novel targeted agents in the treatment of lung cancer, radiosurgery for lung cancer, and reduction of toxicities from thoracic radiation.